Literature DB >> 6897206

M-AMSA in disseminated prostatic carcinoma: a phase II study.

A Drelichman, D A Decker, M Al-Sarraf, C B Dhabuwala.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6897206

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  4 in total

1.  The effect of cimetidine, phenobarbitone and buthionine sulphoximine on the disposition of N-5-dimethyl-9-[(2-methoxy-4-methyl-sulphonylamino)phenylamino]- 4-acridinecarboxamide (CI-921) in the rabbit.

Authors:  J W Paxton; P C Evans; J R Hardy
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Dose-dependent pharmacokinetics of N-5-dimethyl-9-[(2-methoxy-4-methylsulphonylamino)phenylamino]- 4-acridinecarboxamide (CI-921) in rabbits.

Authors:  J W Paxton; P C Evans; R M Singh
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

3.  The clinical pharmacokinetics of N-5-dimethyl-9-[(2-methoxy-4-methyl-sulfonylamino)phenylamino]-4 -acridinecarboxamide (CI-921) in a phase 1 trial.

Authors:  J W Paxton; J R Hardy; P C Evans; V J Harvey; B C Baguley
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

4.  Comparison of the pharmacokinetics and protein binding of the anticancer drug, amsacrine and a new analogue, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino)phenyl-amino] -4-acridinecarboxamide in rabbits.

Authors:  J W Paxton; J L Jurlina
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.